” Item 24, What motivates you to take your osteoporosis medication? Item 25, How motivated are you to keep taking your osteoporosis medication? Perceptions (ten source items) Level of bone fragility; inability to notice osteoporosis evolution; concern about osteoporosis diagnosis; concerns (falls, fractures, disability); treatment constraints; easy to take treatment; treatment efficacy; inability to notice treatment beneficial effects; treatment side-effects Item 16, Do you feel that your osteoporosis medication is easy to take? Item 18, Are the instructions for taking your osteoporosis medication inconvenient for you? Behaviour
(13 source AZD2171 price items) Forgetting/skipping treatment; tricks for remembering treatment; involvement of patient (for BMD test, in decision-making, consulting regularly, seeking information); daily life adaptation to osteoporosis; daily life adaptation to treatment; motivations to take treatment; intention to continue treatment Item 21, Do you ever forget to take your osteoporosis medication? Item 22, Do you ever skip your medication because of unexpected circumstances? Item 23, How do you remind yourself to take your osteoporosis medication? Item 30, “I have become used to taking LY3023414 mw my osteoporosis medication.” Item 31, “I make sure to carefully follow
O-methylated flavonoid the instructions I’m given about taking my osteoporosis medication.” Information (three source items) Need more information/explanation about osteoporosis or treatment; information
from friends or relations; consistency of information Item 17, Did you receive Selleckchem Autophagy inhibitor specific instructions on how to take your osteoporosis medication? Item 32, “The instructions for taking my osteoporosis medication are clear enough.” Patient features (seven source items) Age; diagnosis of osteoporosis; family history of osteoporosis; fracture history; history of BMD testing; treatment; reimbursement None retained The wordings of the French and English version of the questionnaire, as well as the scoring system are provided in Electronic Supplementary Material. ADEOS-12: 12-item adherence and osteoporosis questionnaire BMD bone mass densitometry Other adherence measures The study also assessed medication adherence using two other non-specific adherence measures that had been validated previously, the MPR [20] and the MMAS [21]. The MPR is defined as the ratio between the length of time for which a patient is in possession of prescribed medication and the time since the first prescription. The MPR was determined from data on all medication prescribed since 2002 (first availability of the Thalès database).